The study describes a validated reverse-phase HPLC method for the simultaneous estimation of Meropenem and Sulbactam in combined dosage form. The proposed RP-HPLC method utilizes Hiber C18 column (250 × 4.6 mm i.d., 5 μm), optimum mobile phase consisted of gradient run of initial ratio of Sodium phosphate dibasic (pH-5.0 adjusted with orthophosphoric acid): Acetonitrile (90:10) with the effluent flow rate of 1.0 ml/min, and UV detection wavelength 230 nm. The developed method was statistically validated for linearity, precision, recovery and ruggedness. The method was linear over the range of 50-150 μg/ml for Meropenem and 25-75 μg/ml for Sulbactam. The mean recovery was 100.06% and 100.29% for Meropenem and Sulbactam respectively. The intermediate precision data obtained under different experimental setup was quite concurrent with less critical % RSD. The proposed method can be useful in the quality control of Meropenem and Sulbactam in bulk drug and drug products.
Loading....